Lupus & antiphospholipid syndrome
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with systemic lupus erythematosus (SLE)
Authors' conclusion
Anifrolumab demonstrates efficacy in treating refractory CLE subtypes and lupus non-specific mucocutaneous manifestations in SLE patients.
Study context
- Population
- SLE patients with refractory cutaneous lupus erythematosus (CLE)
- Participants
- 4 patients
- Outcome
- CLASI-A at baseline and post-treatment visits
Methodological detailsadd-on therapy
- Add-on therapy
Main finding
As reported in the abstract
Cutaneous response by patient
- Patient 1: refractory chronic CLE with lupus panniculitis and calcinosis cutis effectively treated
- Patient 2: rapid improvement in generalised discoid lupus; CLASI-A from 40 to 8
- Patient 3: switching from belimumab to anifrolumab led to notable improvement in photosensitivity and tumid lupus
- Patient 4: refractory subacute CLE effectively managed, remarkable cutaneous improvement and successful tapering of prednisone and MMF
Observational data: associations, not effects.
Original publication
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE. Lupus Sci Med. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →